Susquehanna International Group, LLP Nymox Pharmaceutical Corp Put Options Transaction History

Susquehanna International Group, LLP

16 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2022 Nov 14, 2022	SELL	$0.22 - $0.61 $88 - $244	-400 Reduced 3.03%	12,800 $5,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $1.41 $1,520 - $5,640	-4,000 Reduced 23.26%	13,200 $6,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.0 $5,203 - $8,600	-4,300 Reduced 20.0%	17,200 $22,000
Q4 2020 Feb 16, 2021	SELL	$1.84 - $2.83 $2,392 - $3,679	-1,300 Reduced 5.7%	21,500 $53,000
Q3 2020 Nov 16, 2020	SELL	$2.3 - $3.66 $11,040 - $17,568	-4,800 Reduced 17.39%	22,800 $56,000
Q1 2020 May 15, 2020	BUY	$1.69 - $3.88 $24,336 - $55,872	14,400 Added 109.09%	27,600 $65,000
Q4 2019 Feb 14, 2020	SELL	$1.73 - $2.42 $33,908 - $47,432	-19,600 Reduced 59.76%	13,200 $29,000
Q3 2019 Nov 14, 2019	SELL	$1.41 - $2.12 $14,523 - $21,836	-10,300 Reduced 23.9%	32,800 $60,000
Q2 2019 Aug 14, 2019	BUY	$1.33 - $2.12 $39,501 - $62,964	29,700 Added 221.64%	43,100 $62,000
Q1 2019 May 15, 2019	SELL	$1.57 - $2.71 $77,558 - $133,874	-49,400 Reduced 78.66%	13,400 $26,000
Q4 2018 Feb 14, 2019	SELL	$1.31 - $2.53 $331,299 - $639,837	-252,900 Reduced 80.11%	62,800 $82,000
Q3 2018 Nov 14, 2018	SELL	$2.46 - $3.7 $1,230 - $1,850	-500 Reduced 0.16%	315,700 $777,000
Q2 2018 Aug 14, 2018	BUY	$3.12 - $4.33 $269,568 - $374,112	86,400 Added 37.6%	316,200 $1.06 Million
Q1 2018 May 15, 2018	SELL	$3.09 - $4.43 $593,898 - $851,446	-192,200 Reduced 45.55%	229,800 $972,000
Q4 2017 Feb 14, 2018	BUY	$3.29 - $4.06 $40,138 - $49,531	12,200 Added 2.98%	422,000 $1.39 Million
Q3 2017 Nov 14, 2017	BUY	$3.36 - $4.02 $1.38 Million - $1.65 Million	409,800	409,800 $1.57 Million

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.